Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Colitis is swelling (inflammation) of the large intestine (colon). It can have many different causes, including infections including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders, lack of blood flow, or past radiation to the large bowel. Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea, and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.
The Colitis Drugs in Development market research report provides an overview of the colitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colitis and features dormant and discontinued projects.
What are the targets of the colitis pipeline drugs market?
Some of the targets of the colitis pipeline drugs market are Glucocorticoid Receptor, 15-Hydroxyprostaglandin Dehydrogenase [NAD(+)], Androgen Receptor, Aryl Hydrocarbon Receptor, Calcineurin, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Caspase, DNA Directed RNA Polymerase, and Interleukin 23 Receptor.
Colitis pipeline drugs market, by targets
For more target insights, download a free report sample
What are the mechanisms of action of the colitis pipeline drugs market?
Some of the mechanisms of action of the colitis pipeline drugs market are Glucocorticoid Receptor Agonist, 15-Hydroxyprostaglandin Dehydrogenase [NAD(+)] Inhibitor, Androgen Receptor Antagonist, Aryl Hydrocarbon Receptor Agonist, Calcineurin Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Caspase 1 Inhibitor, DNA Directed RNA Polymerase Inhibitor, and Interleukin 23 Receptor Antagonist.
Colitis pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
What are the routes of administration in the colitis pipeline drugs market?
Some of the routes of administration in the colitis pipeline drugs market are oral, rectal, intravenous, topical, intradermal, intraperitoneal, intratracheal, and vaginal.
Colitis pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
What are the molecule types in the colitis pipeline drugs market?
The molecule types in the colitis pipeline drugs market are small molecule, monoclonal antibody, biologic, polysaccharide, synthetic peptide, antibody, fusion protein, gene therapy, inactivated vaccine, peptide, and recombinant protein.
Colitis pipeline drugs market, by molecule types
For more molecule type insights, download a free report sample
Which are the key companies in the colitis pipeline drugs market?
Some of the key companies in the colitis pipeline drugs market are First Wave BioPharma Inc, Servatus Ltd, Symbiotix Biotherapies Inc, Wuhan LL Science and Technology Development Co Ltd, Meters Biopharma Inc, Aclaris Therapeutics Inc, Alfasigma SpA, Amgen Inc, Apollo Endosurgery Inc, and Artus Therapeutics Inc.
Colitis pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report overview
| Targets | Glucocorticoid Receptor, 15-Hydroxyprostaglandin Dehydrogenase [NAD(+)], Androgen Receptor, Aryl Hydrocarbon Receptor, Calcineurin, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Caspase, DNA Directed RNA Polymerase, and Interleukin 23 Receptor |
| Mechanisms of Action | Glucocorticoid Receptor Agonist, 15-Hydroxyprostaglandin Dehydrogenase [NAD(+)] Inhibitor, Androgen Receptor Antagonist, Aryl Hydrocarbon Receptor Agonist, Calcineurin Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Caspase 1 Inhibitor, DNA Directed RNA Polymerase Inhibitor, and Interleukin 23 Receptor Antagonist |
| Routes of Administration | Oral, Rectal, Intravenous, Topical, Intradermal, Intraperitoneal, Intratracheal, and Vaginal |
| Molecule Types | Small Molecule, Monoclonal Antibody, Biologic, Polysaccharide, Synthetic Peptide, Antibody, Fusion Protein, Gene Therapy, Inactivated Vaccine, Peptide, and Recombinant Protein |
| Key Companies | First Wave BioPharma Inc, Servatus Ltd, Symbiotix Biotherapies Inc, Wuhan LL Science and Technology Development Co Ltd, Meters Biopharma Inc, Aclaris Therapeutics Inc, Alfasigma SpA, Amgen Inc, Apollo Endosurgery Inc, and Artus Therapeutics Inc |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).
- Reviews of pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Key players involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- Assessment of Colitis (Gastrointestinal) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Colitis (Gastrointestinal).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Aclaris Therapeutics Inc
Alfasigma SpA
Amgen Inc
Apollo Endosurgery Inc
Artus Therapeutics Inc
Chiesi Farmaceutici SpA
Citryll BV
Dr. Falk Pharma GmbH
Drug Farm Inc
Elgia Therapeutics Inc
enGene Inc
F. Hoffmann-La Roche Ltd
First Wave BioPharma Inc
Himuka AM Pharma Corp
Immodulon Therapeutics Ltd
Immuron Ltd
Jubilant Therapeutics Inc
MAKScientific LLC
Nippon Kayaku Co Ltd
Privo Technologies Inc
Protagonist Therapeutics Inc
Protheragen Inc
Riptide Bioscience Inc
Scholar Rock Inc
Servatus Ltd
Soligenix Inc
Symbiotix Biotherapies Inc
TaiRx Inc
TPCera Ltd
Vascular Biogenics Ltd
Vedanta Biosciences Inc
Vitality Biopharma Inc
Wuhan LL Science and Technology Development Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the colitis pipeline drugs market?
Some of the targets of the colitis pipeline drugs market are Glucocorticoid Receptor, 15-Hydroxyprostaglandin Dehydrogenase [NAD(+)], Androgen Receptor, Aryl Hydrocarbon Receptor, Calcineurin, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Caspase, DNA Directed RNA Polymerase, and Interleukin 23 Receptor.
-
What are the mechanisms of action of the Colitis pipeline drugs market?
Some of the mechanisms of action of the Colitis pipeline drugs market are Glucocorticoid Receptor Agonist, 15-Hydroxyprostaglandin Dehydrogenase [NAD(+)] Inhibitor, Androgen Receptor Antagonist, Aryl Hydrocarbon Receptor Agonist, Calcineurin Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Caspase 1 Inhibitor, DNA Directed RNA Polymerase Inhibitor, and Interleukin 23 Receptor Antagonist.
-
What are the routes of administration in the Colitis pipeline drugs market?
Some of the routes of administration in the Colitis pipeline drugs market are oral, rectal, intravenous, topical, intradermal, intraperitoneal, intratracheal, and vaginal.
-
What are the molecule types in the Colitis pipeline drugs market?
The molecule types in the Colitis pipeline drugs market are small molecule, monoclonal antibody, biologic, polysaccharide, synthetic peptide, antibody, fusion protein, gene therapy, inactivated vaccine, peptide, and recombinant protein.
-
Which are the key companies in the Colitis pipeline drugs market?
Some of the key companies in the Colitis pipeline drugs market are First Wave BioPharma Inc, Servatus Ltd, Symbiotix Biotherapies Inc, Wuhan LL Science and Technology Development Co Ltd, Meters Biopharma Inc, Aclaris Therapeutics Inc, Alfasigma SpA, Amgen Inc, Apollo Endosurgery Inc, and Artus Therapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Other Diseases reports